X

Health & Biotech

Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.

Health: Admedus shares fly 40pc on first trading day in six months

Shares in medtech Admedus (ASX:AHZ) have flown 40 per cent on their first trading day in six months, after the company netted…

Dr Boreham’s Crucible: Recce Pharmaceuticals, the emerging superbug killer

If there’s one reason to fear going into hospital a bit off-colour and emerging seriously ill, it’s the strains of…

Health: Oncosil stays hopeful with regulators, shares move higher

Cancer treatment company Oncosil Medical (ASX:OSL) has had a rough trot on the regulatory front so far this year. But…

‘People want revenues and a genuine business’: how ASX pot stocks are maturing

Two and a half years ago, cannabis was so hot Stemcell United (ASX:SCU) went from 1 cent to 19 cents…

Orthocell’s technology might have helped cure Superman

On Wednesday, small cap ASX biotech Orthocell (ASX:OCC) reported that its collagen scaffold technology CelGro was restoring some function and movement to…

Clinuvel on top of the world after FDA approval caps off rise of 4000%

The FDA’s decision on Clinvel Pharmaceuticals’ (ASX: CUV) SCENESSE treatment for erythropoietic protoporphyria capped off a stellar ride that’s lasted…

Weed Week: Australia’s cannabis legalisation is all over the joint

It's been another interesting week in the realm of Australian cannabis regulation. For starters, the ACT legislature's recent decision to…

The Health Kick Podcast with Tim Boreham: Kazia Therapeutics

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the stethoscope and picking up the microphone for another…

Clinuvel surges to all-time high on US green light

Ending years of uncertainty, shares in skin treatment specialist Clinuvel (ASX:CUV) surged to all-time highs this morning after it received…

Biotech: With Phase II trials underway, Dimerix eyes first-mover advantage in the US market

When it comes to the listed biotech space, getting the communication right is critical. For starters, it's a sector geared…

Health: Zelda wants to buy a private US-based medicinal cannabis company

Zelda Therapeutics (ASX:ZLD) wants to acquire private US-based medicinal cannabis and cannabinoid science company Ilera Therapeutics in an all-scrip deal. This…

These are the three biggest opportunities for digital transformation in pharma

The healthcare sector has been perhaps the slowest of all industries to embrace digitisation -- and in fewer countries is…